Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML.

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Perl AE
  • Martinelli G
  • Cortes JE
  • Neubauer A
  • Berman E
  • Paolini S
  • Baer MR
  • Larson RA
  • Ustun C
  • Fabbiano F
  • Erba HP
  • Di Stasi A
  • Stuart R
  • Olin R
  • Kasner M
  • Ciceri F
  • Chou WC
  • Podoltsev N
  • Recher C
  • Yokoyama H
  • Hosono N
  • Yoon SS
  • Lee JH
  • Pardee T
  • Fathi AT
  • Liu C
  • Hasabou N
  • Liu X
  • Bahceci E
  • Levis MJ

Grupos

Abstract

Patients with relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene ( FLT3 ) infrequently have a response to salvage chemotherapy. Gilteritinib is an oral, potent, selective FLT3 inhibitor with single-agent activity in relapsed or refractory FLT3 -mutated AML.

Datos de la publicación

ISSN/ISSNe:
0028-4793, 1533-4406

NEW ENGLAND JOURNAL OF MEDICINE  MASSACHUSETTS MEDICAL SOC

Tipo:
Article
Páginas:
1728-1740
PubMed:
31665578
Factor de Impacto:
18,291 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 1.080

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Campos de Estudio

Compartir